Literature DB >> 26984297

[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

M von Laffert1, P Schirmacher2, A Warth2, W Weichert3, R Büttner4, R M Huber5, J Wolf6, F Griesinger7, M Dietel8, C Grohé9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26984297     DOI： 10.1007/s00292-016-0152-1

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


× No keyword cloud information.
  33 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer.

Authors:  Anne McLeer-Florin; Sylvie Lantuéjoul
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

3.  A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.

Authors:  Kim Gruber; Martin Kohlhäufl; Godehard Friedel; German Ott; Claudia Kalla
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

4.  Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.

Authors:  M I Ilie; C Bence; V Hofman; E Long-Mira; C Butori; L Bouhlel; S Lalvée; J Mouroux; M Poudenx; J Otto; C H Marquette; P Hofman
Journal:  Ann Oncol       Date:  2014-10-24       Impact factor: 32.976

5.  Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

Authors:  Christina I Selinger; Toni-Maree Rogers; Prudence A Russell; Sandra O'Toole; Poyee Yip; Gavin M Wright; Zoe Wainer; Lisa G Horvath; Michael Boyer; Brian McCaughan; Maija Rj Kohonen-Corish; Stephen Fox; Wendy A Cooper; Benjamin Solomon
Journal:  Mod Pathol       Date:  2013-06-07       Impact factor: 7.842

6.  Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

Authors:  Spasenija Savic; Joachim Diebold; Anne-Katrin Zimmermann; Wolfram Jochum; Betty Baschiera; Susanne Grieshaber; Luigi Tornillo; Bettina Bisig; Keith Kerr; Lukas Bubendorf
Journal:  Lung Cancer       Date:  2015-05-21       Impact factor: 5.705

7.  Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

Authors:  Shengxiang Ren; Fred R Hirsch; Marileila Varella-Garcia; Dara L Aisner; Theresa Boyle; Caicun Zhou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

8.  Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

Authors:  Florian Cabillic; Audrey Gros; Frédéric Dugay; Hugues Begueret; Laura Mesturoux; Dan Cristian Chiforeanu; Leila Dufrenot; Vincent Jauffret; Dominique Dachary; Romain Corre; Alexandra Lespagnol; Gwendoline Soler; Julien Dagher; Véronique Catros; Michèle Le Calve; Jean-Philippe Merlio; Marc-Antoine Belaud-Rotureau
Journal:  J Thorac Oncol       Date:  2014-03       Impact factor: 15.609

9.  New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC-in situ hybridization assay.

Authors:  Hiroaki Nitta; Koji Tsuta; Akihiko Yoshida; Steffan N Ho; Brian D Kelly; Lauren B Murata; Jerry Kosmeder; Katie White; Sandra Ehser; Penny Towne; Crystal Schemp; Abigail McElhinny; Jim Ranger-Moore; Chris Bieniarz; Shalini Singh; Hitoshi Tsuda; Thomas M Grogan
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

10.  Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Authors:  Esther Conde; Ana Suárez-Gauthier; Amparo Benito; Pilar Garrido; Rosario García-Campelo; Michele Biscuola; Luis Paz-Ares; David Hardisson; Javier de Castro; M Carmen Camacho; Delvys Rodriguez-Abreu; Ihab Abdulkader; Josep Ramirez; Noemí Reguart; Marta Salido; Lara Pijuán; Edurne Arriola; Julián Sanz; Victoria Folgueras; Noemí Villanueva; Javier Gómez-Román; Manuel Hidalgo; Fernando López-Ríos
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240
View more
  2 in total

Review 1.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

2.  [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].

Authors:  D F Heigener; M Horn; M Reck
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.